Handelsavisen
prelaunch
20
203690.KQ KOSDAQ Personal Products

203690.Kq

$121,00
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
ROE
Net margin
Debt / equity
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

The company operates in the Personal Products industry, focusing on the development and commercialization of biotechnology-based solutions for personal care and health applications.

Business. The company operates in the Personal Products industry, focusing on the development and commercialization of biotechnology-based solutions for personal care and health applications.

Classification92 %
SectorConsumer Non-Cyclicals
Business sectorPersonal & Household Products & Services
IndustryPersonal Products
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
not yet wired
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 203690.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples · THIS SECTOR−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 203690.KQ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the Personal Products industry, focusing on the development and commercialization of biotechnology-based solutions for personal care and health applications.

    Classification92 %
    SectorConsumer Non-Cyclicals
    Business sectorPersonal & Household Products & Services
    IndustryPersonal Products
    AI synthesis
    GENERATED

    The company's capital structure is characterized by a lack of detailed liquidity metrics, as no balance-sheet inputs are available and no going-concern language is present in the source documents. This absence of data prevents a full assessment of its liquidity position. The valuation snapshot does not provide additional insight into the company's financial health, as it remains unpopulated.

    Profitability and returns cannot be meaningfully assessed due to the absence of financial metrics in the valuation snapshot. Without access to key performance indicators such as return on invested capital (ROIC), gross margins, or net profit margins, it is not possible to compare the company's performance against industry benchmarks or cohort medians.

    The company's segments and geographic exposure are not disclosed in the available data. There is no information on revenue concentration by product line or region, which limits the ability to assess the diversification of its revenue streams or exposure to specific markets.

    The company's growth trajectory is also unclear. The outlook section does not provide numeric deltas or revenue history, making it difficult to determine whether the company is experiencing growth, stagnation, or contraction. Without forward-looking guidance or historical performance data, the company's future prospects remain speculative.

    Risk factors are limited to the observation that liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in the source documents. The dilution risk is currently rated as low, but the lack of detailed financial data means that the potential for future dilution remains uncertain. No adjustments have been applied to the valuation metrics, as no relevant data is available for such analysis.

    Recent events, including filings and transcripts, are not disclosed in the available data. The absence of such information prevents an assessment of the company's recent strategic moves, management commentary, or regulatory developments that may impact its operations or valuation.

    Key takeaways
    • The company's liquidity position cannot be assessed due to the absence of balance-sheet data and no going-concern language in the source documents.
    • Profitability and returns metrics are not available, preventing a comparison against industry benchmarks.
    • The company's segments and geographic exposure are not disclosed, limiting the understanding of its revenue diversification.
    • Growth trajectory is indeterminate due to the lack of numeric deltas and revenue history.
    • Dilution risk is currently low, but the lack of detailed financial data means the potential for future dilution remains uncertain.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $121,00
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    Net cash
    Current ratio
    Debt / equity
    ROA
    ROE
    Cash conversion
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskUnknown

    Benchmarks vs cohort

    No cohort benchmark data available for this issuer yet.

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    Source documents
    • 203690.KQ Market data — financials · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    203690.KQCanonical
    KOSDAQ · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskUnknown

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage